Multiple monitored electroconvulsive therapy
This article was originally published in The Gray Sheet
Executive Summary
CMS' Nov. 19 decision not to cover MMECT follows a 1December 2001 HHS Office of the Inspector General report which concluded that the procedure is being used too frequently (2"The Gray Sheet" Jan. 14, 2002, p. 32). The agency found that literature supporting the use of MMECT "reflected substantial methodological shortcomings." In addition, evidence concluded that MMECT may pose additional safety risks over conventional one-time ECT for patients with affective disorders or other psychiatric disorders without a balancing clinical benefit, the decision memorandum states. The agency says it is open to considering evidence for narrowly defined, non-routine uses of MMECT if it is brought to CMS' attention in the future; however, no comments from professional organizations or the general public were submitted during the course of the review...
You may also be interested in...
CMS Should Reconsider Electroconvulsive Therapy CPT Code – HHS OIG
The Centers for Medicare & Medicaid Services will evaluate the appropriateness of multiple-monitored electroconvulsive therapy in its April review of CPT codes, following a December 2001 recommendation by the HHS Office of the Inspector General
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.